Kate Lewis, VP, Program Lead, Beta-Thalassemia. Bluebird Bio
Robin LeWinter, PhD, ISMPP CMPP, Senior Director, Medical Communications, Orchard Therapeutics

Moderator: Eugene Tombler, PhD, Medical Insights Director, CMC – Connect

Join us for a panel discussion among industry publications experts around the considerations and challenges for publication planning in support of one of the most rapidly evolving areas of therapeutic development – gene therapies. Communications around gene therapies may require adjustment from conventional experience regarding timing and scope of publication plans. Panelists will educate on similarities and differences regarding publication planning for conventional therapies vs those for gene therapies and how to best navigate the different requirements.

Learning objectives:

• Recognize the unique factors around gene therapy pre-clinical and clinical development that create the need for early initiation of publication plans
• Recall the potential challenges of publication planning for gene therapies, how they may differ from planning around more traditional therapeutics and how they may be effectively addressed
• Relate the minimum requirements of a lexicon and communication plan in support of early publications